Pharmacy Podcast Network

The biopharmaceutical industry is experiencing rapid growth, and the need for a well-trained workforce comes with that. In this episode of Occupation Station, Diane Donato talks with Dr. Michelle Lewis, executive director for the Stack Family Center for Biopharmaceutical Education and Training (CBET) and David Stack, member of the ACPHS Board of Trustees, and CEO of Pacira Pharmaceuticals about how CBET is meeting the hiring needs of the biopharmaceutical industry. CBET was created as an outgrowth of Albany College of Pharmacy and Health Sciences (ACPHS) after the demand for biopharmaceutical training became apparent. Since CBET opened, industry leaders have been reaching out to CBET to help them grow their workforce, and ACPHS graduates have been enrolling in training to advance their careers in biopharmaceuticals. CBET has the added advantage of being able to offer manufacturing services, becoming a crucial partner for many start-up companies. Stack and Dr. Lewis talk about how the industry collaborates with CBET, how ACPHS graduates learn valuable new skills, and how healthcare will grow with advanced biopharmaceutical capabilities.

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.

i3Health has developed a dual part education activity for pharmacists on Multiple myeloma with special guest Joseph A. Kalis, PharmD, BCOP and Ambulatory Oncology Pharmacy Specialist. 

Look up the word, grit, in the dictionary and you'll see a picture of Chichi Momah, PharmD., and owner of Springfield Pharmacy in Pennsylvania. Momah opened her brand new start from scratch pharmacy in 2012. She weathered some hard times but kept-on-keepin'-on. She shares how taking leadership, finances and other courses helped her bring her pharmacy along and then how she put it in high-gear with immunizations. Momah is the real deal and you'll be inspired and motivated by her remarkable story.

The public’s perception of pharmacist’s is generally limited to a retail chain environment even though community retail plays one part of many roles of pharmacists. Community Pharmacy, Hospital Pharmacy, Compounding Pharmacy, Consulting Pharmacy, Ambulatory Care pharmacy, and Regulatory Pharmacy as a few other sectors of healthcare where pharmacists work to keep the public safe. We talk with Dr. Sue Ojageer PharmD, CPGx, PACS – as an author, pharmacogenomics pharmacist, and healthcare influencer about her transforming role from community pharmacist to consultant entrepreneur. Next we welcome back Josh Kent and Steve McCarthy from Cannabis Pharmacy to talk about getting your community pharmacy started with CBD and Cannabis focused business focusing on pain, anxiety, and sleep supplements.

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

About New Expanded Medicare Guidelines

About Hello Dexcom

Dexcom Provider website

About Medicaid coverage

Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.

Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.

A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.

Brief Safety Statement

BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom Clarity Safety Information

The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

1. Dexcom G7 User Guide

So much incredible progress has been made in the management and treatment of breast cancer, largely thanks to advances in available therapies and drugs. A good understanding of pharmacology is key to selecting the correct regimen and providing counseling to your patients. This week, are so fortunate to be joined by special guest Dr. Danielle Roman, PharmD, who is an Oncology Clinical Pharmacy Specialist at West Penn Allegheny Oncology Network in Pennsylvania, as she helps us navigate breast cancer pharmacology.

Link: https://www.thefellowoncall.com/tfocpodcast/breastcancerpharm 

Hyperemesis Gravidarum (HG) is a potentially life-threatening pregnancy disease that may cause weight loss, malnutrition, dehydration, and debility due to severe nausea and/or vomiting, and may cause long-term health issues for mother and baby(ies). It occurs in up to 3% of pregnant women and may last the entire pregnancy, which can lead to malnourished. Dr. Danielle Plummer has unfortunately been a three-time survivor of HG and she is the founder and CEO of HG clinical solutions (www.hgclinicalsolutions.com). Please visit that website and learn more. She offers personalized medication planning and patient advocacy in addition to educating providers on HG disease state. She has women around the world reaching out to her for advice and support, and she is looking forward to the day that PGx is utilized in all the countries that she is supporting. www.HGPharmacist.com is a link to Danielle's free ebook called "Dear ER doctor, Believe Us" There is also a FaceBook support group: www.facebook.com/groups/hgsolutions. "Coming Soon" is the course called "Preparing for a Hyperemesis Pregnancy". Connect with Danielle to sign up.